Jump to:
loading...| Preferred Name |
Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
| Synonyms |
|
|
| ID |
http://purl.bioontology.org/ontology/HCPCS/Q2054 |
|
| cui |
C5551177 |
|
| HAC |
N=No maintenance for this code |
|
| HAD |
20211001 |
|
| HAQ |
0 |
|
| HBT |
O1E=Other drugs |
|
| HCC |
C=Carrier judgment |
|
| HCD |
20211001 |
|
| HMP |
A=Not applicable as HCPCS priced under one methodology |
|
| HPI |
51=Drugs |
|
| HTS |
P=Lump sum purchase of DME, prosthetics, orthotics 1=Medical care |
|
| notation |
Q2054 |
|
| prefLabel |
Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
| tui |
T200 |
|
| subClassOf |
http://purl.bioontology.org/ontology/HCPCS/Level%202%3A%20Q2004-Q2056 |